To help stop cancer misinformation on social media, health care providers can participation in social networks to see the types of content to which their patients are exposed, disseminate evidence‐based information, and correct misinformation. acsjournals.onlinelibrary.wiley.com/doi/10.3322/ca… Stacy Loeb, MD

Germline variants with therapeutic implications in prostate cancer. It has been a pleasure to work with Masoud Bitaraf and Nima Sharifi in this review focused on the role of HSD3B1 and BRCA2👇sciencedirect.com/science/articl…

Terbium-161 vs lutetium-177: Comparing next-gen radioligands for #ProstateCancer. Michael Hofman Peter Mac Cancer Centre joins Oliver Sartor, MD East Jefferson General Hospital to discuss the #VIOLET study evaluating Terbium-161 PSMA therapy in #mCRPC. #WatchNow > bit.ly/46AXlG8

I'm pleased to launch a new series, "Science Matters." We’ll explore why science matters, and which scientific 'matters' are key to translating cancer breakthroughs into better care for patients everywhere. I hope you enjoy the first installment! connection.asco.org/do/science-mat…

APCCC is already a classic, but have you checked the program for the International Prostate Cancer Symposium #IPCS26? The 2 days before APCCC, available both in person and on-line. onlineevent.ch/APCCC/2026

CHAARTED Ten-year survival rates: Time to re-think de-escalation! Achieving a PSA nadir below 0.2 ng/mL within 6 months is a strong predictor of overall survival, supporting its role in response-adapted de-escalation strategies. Annals of Oncology ESMO - Eur. Oncology ECOG-ACRIN Cancer Research Group Elizabeth Plimack MD

👏 Congratulations to Félix Guerrero-Ramos from Hospital Universitario 12 de Octubre for this valuable collaboration between Urology & Oncology. A clear example of unity driving progress Daniel Castellano

A very sweet ending to a great #IUCS25 meeting!

"We added the requested experiments and thank the reviewers for their helpful suggestions"

Abstract submission and scholar-in-training award applications are open until 6th November AACR

Submit an abstract by November 6 for the AACR Conference on Innovations in Prostate Cancer Research and Treatment (Jan 20-22; Boston), chaired by Peter S. Nelson, Elena Castro, Patrick G. Pilié, and Eliezer M. Van Allen. brnw.ch/21wVDBa #AACRprostate26 Elena Castro

🎂 El Centro de Oncología Experimental del #Hospital12deOctubre cumple dos años. 🔬 Más de 100 investigadores y 156 estudios activos centrados en los tumores de mayor impacto. 👉 Referente nacional e internacional en cáncer. + info: c.madrid/fzc6a1 #somosdel12

👉 For ESMO Members! ESMO Handbook of Cancer Genetics and Genomics Edited by leading experts, delivering genomic literacy for clinical decision making: inherited genetic syndromes, key somatic and germline mutations, and more! 🔗 Download now: ow.ly/x2Um50WZe9Q

#ESMO25 will be a fantastic meeting for GU oncology! Join us to discuss 5 impactful phase 3 trials #ProstateCancer ESMO - Eur. Oncology

And don’t miss the #ESMO25 GU Prostate Mini-Oral session for more exciting new data ESMO - Eur. Oncology

Submit an abstract by November 6 for the AACR Conference on Innovations in Prostate Cancer Research and Treatment (Jan 20-22; Boston), chaired by Peter S. Nelson, Elena Castro, Patrick G. Pilié, and Eliezer M. Van Allen. brnw.ch/21wW81d #AACRprostate26 Elena Castro

👉Our new ESMO Open paper just OUT! Check the risk of VTE of PARPi in our meta-analysis! ESMO - Eur. Oncology OncoAlert Yüksel Ürün Toni Choueiri, MD Erman Akkus Advanced Prostate Cancer Consensus Conference Rana McKay, MD, FASCO #cancer #Oncology #MedX Neeraj Agarwal, MD, FASCO Maxine Sun silke gillessen Elena Castro

‼️LAST CALL 📍La Semana de la Ciencia de ASEICA 2025 comenzará con... ⚫RETREAT #ASEICAMed Keynote🗣️Ignacio Melero Clínica Universidad de Navarra Cima Universidad de Navarra 📅7OCT 🏟️Bilbao ▶️Ciencia y Networking ‼️ Posibilidad de Registro único o a todo el #ASEICACongress aseica.es/aseicamed-retr…